All News

At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.

In this study, researchers observed no association between black race and the risk of SREs and overall mortality in men with bone metastatic castration-resistant prostate cancer.

In this study, neutrophil extracellular traps were found to prompt the lethal blood clots and inflammation that occur in some patients with COVID-19.

At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in patients with brain metastasis-negative, metastatic triple-negative breast cancer met its primary end point of progression-free survival.

The FDA lifted the partial clinical hold on the on the pivotal phase 2 trial of camidanlumab tesirine (Cami) – designed to evaluate the antibody drug conjugate in patients with relapsed or refractory Hodgkin lymphoma.

The expert oncologist discussed the findings of the COVID-19 and Cancer Consortium and how the results of the consortium should inform conversations with patients with cancer.

The study of temsirolimus and cetuximab versus temsirolimus alone in patients with recurrent or metastatic cetuximab-resistant head and neck cancer did not meet its primary end point of improved progression-free survival.

Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.

This study found that Hispanic adults trust a wide variety of health information sources, indicating the need for targeted and tailored information from healthcare providers.

However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient population, regardless of CHIP status.

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

The findings support ctDNA testing in patients who are undergenotyped at the time of diagnosis and as a primary option at the time of progression on targeted therapies.

In this open-label, randomized, phase 2 trial, treatment with trastuzumab deruxtecan led to significant improvements in response and overall survival in patients with HER2-positive gastric cancer.

Fam-trastuzumab deruxtecan-nxki (Enhertu) showed favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non-small cell lung cancer.

The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.

The study demonstrated modest survival benefits in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum (EP).

Researchers have developed a new blood test that may help in identifying individuals who are likely to develop hepatocellular carcinoma.

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

The FDA approved avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

The associate director for Patient Outcomes in the Oncology Center of Excellence at the FDA spoke about the new pilot program and how it could aid patients and providers moving forward.

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

The trial is evaluating tisotumab vedotin administered every 3 weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer.

The FDA approved pembrolizumab for IV injection for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.

Combining tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non-small cell lung cancer.

The FDA approved phesgo for injection under the skin to treat adult patients with early and metastatic HER2-positive breast cancer.

Patients enrolled in this open-label trial have p53-mutated extensive disease small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924.

The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Nirav Niranjan Shah, MD, discussed the study of patients with relapsed diffuse large B-cell lymphoma achieving only a PET/CT positive partial remission and what it means for this patient population.

Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.